⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26122417 | 0.84 | — | — | |
| SCHEMBL20924688 | 0.82 | AKT1 (0.32) | — | |
| SCHEMBL26123929 | 0.81 | AKT1 (0.34) | — | |
| SCHEMBL26921579 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL26123745 | 0.79 | AR (0.32) | — | |
| SCHEMBL24329423 | 0.79 | — | — | |
| SCHEMBL29582879 | 0.79 | — | — | |
| SCHEMBL30546467 | 0.79 | AR (0.32) | — | |
| SCHEMBL14911427 | 0.77 | CA1 (0.38) | — | |
| SCHEMBL27435341 | 0.77 | CA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479054-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4320112-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308557-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| CN-117157286-A | Pyridyl-substituted oxo-isoindoline compounds | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| CN-116669769-A | Piperidinyl small molecule degradants of HELIOS and methods of use | 达纳－法伯癌症研究所公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023158708-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116261456-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022216644-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022216573-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022081976-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022036204-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3820574-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012337-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |